Compare · LAB vs RVTY
LAB vs RVTY
Side-by-side comparison of Standard BioTools Inc. (LAB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LAB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $13.93B, about 54.6x LAB ($255.2M).
- Over the past year, LAB is down 49.6% and RVTY is up 36.7% - RVTY leads by 86.3 points.
- LAB has been more active in the news (9 items in the past 4 weeks vs 6 for RVTY).
- RVTY has more recent analyst coverage (20 ratings vs 5 for LAB).
- Company
- Standard BioTools Inc.
- Revvity Inc.
- Price
- $0.65-0.08%
- $124.78+1.46%
- Market cap
- $255.2M
- $13.93B
- 1M return
- -15.85%
- +15.48%
- 1Y return
- -49.61%
- +36.67%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 9
- 6
- Recent ratings
- 5
- 20
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest LAB
- SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 25,729 shares, decreasing direct ownership by 2% to 1,480,823 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 28,195 shares, decreasing direct ownership by 1% to 2,534,859 units (SEC Form 4) (for withholding tax)
- President & CEO Egholm Michael covered exercise/tax liability with 97,627 shares, decreasing direct ownership by 2% to 6,137,704 units (SEC Form 4) (for tax liability)
- SEC Form S-8 filed by Standard BioTools Inc.
- SEC Form S-8 filed by Standard BioTools Inc.
- SEC Form 10-Q filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Standard BioTools Reports Second Quarter 2026 Financial Results
- President & CEO Egholm Michael covered exercise/tax liability with 362,625 shares, decreasing direct ownership by 5% to 6,235,331 units (SEC Form 4) (tax withholding)
- SEC Form 425 filed by Standard BioTools Inc.
Latest RVTY
- Director Michas Alexis P gifted 285 shares (SEC Form 4)
- Officer Goldberg Joel S gifted 27,785 shares and received a gift of 27,785 shares, decreasing direct ownership by 67% to 13,729 units (SEC Form 4)
- Officer Singh Prahlad R. gifted 67,286 shares and received a gift of 67,286 shares, decreasing direct ownership by 59% to 46,026 units (SEC Form 4)
- SEC Form 10-Q filed by Revvity Inc.
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Second Quarter of 2026
- Revvity Board Declares Quarterly Dividend
- Vice President and CAO Gonzales Anita sold $9,306 worth of shares (85 units at $109.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,201 units (SEC Form 4)
- Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026